Key result
Second-generation cryoballoon ablation for paroxysmal atrial fibrillation in patients ≥75 years achieved a 1-year success rate similar to that in younger patients (81.1% vs. 84.9%, P=0.54).
Why the study?
Does second generation cryoballoon ablation have similar efficacy and safety in patients ≥75 years compared to patients <75 years with drug-resistant paroxysmal atrial fibrillation?
Population
159 patients with drug-resistant paroxysmal atrial fibrillation undergoing pulmonary vein isolation…
Comparison
Second generation cryoballoon ablation for… vs Second generation cryoballoon ablation for…
Design
Cohort
Follow-up
1-year
Authors
Loading...
Supports cryoballoon ablation for paroxysmal AF in patients ≥75 years; hypothesis-generating and should not yet change practice.
Cohort (n=159)
Yes
Does second generation cryoballoon ablation have similar efficacy and safety in patients ≥75 years compared to patients <75 years with drug-resistant paroxysmal atrial fibrillation?
Absolute Event Rate: 81.1% vs 84.9%
p-value: p=0.54
Second generation cryoballoon ablation is a feasible, safe, and effective treatment for drug-resistant paroxysmal atrial fibrillation in patients over 75 years, with outcomes comparable to younger patients.
Abugattas et al. (2017) conducted a cohort in Drug-resistant paroxysmal atrial fibrillation (n=159). Age ≥75 years (undergoing cryoballoon ablation) vs. Age <75 years was evaluated on Global success rate at 1 year (p=0.54). Second-generation cryoballoon ablation for paroxysmal atrial fibrillation in patients ≥75 years achieved a 1-year success rate similar to that in younger patients (81.1% vs. 84.9%, P=0.54).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: